Evidence map›Paper›PMID 26109071›Full record

ArticleThe Journal of biological chemistry2015

RasGAP Shields Akt from Deactivating Phosphatases in Fibroblast Growth Factor Signaling but Loses This Ability Once Cleaved by Caspase-3.

Katia Cailliau, Arlette Lescuyer, Anne-Françoise Burnol, Álvaro Cuesta-Marbán, Christian Widmann, Edith Browaeys-Poly

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling.International journal of molecular sciences · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Katia CailliauFrom the Université de Lille 1, Sciences et Technologies, Team Signal Division Regulation, CNRS UMR 8576, SN3, 59655 Villeneuve d'Ascq Cedex, France, katia.maggio@univ-lille1.fr.
Arlette LescuyerFrom the Université de Lille 1, Sciences et Technologies, Team Signal Division Regulation, CNRS UMR 8576, SN3, 59655 Villeneuve d'Ascq Cedex, France.
Anne-Françoise BurnolINSERM, U1016, Institut Cochin, Paris, France, CNRS UMR8104, Institut Cochin, 22 rue Méchain, 75014 Paris, France, the Université Paris Descartes, Sorbonne Paris Cité, 24 Rue du Faubourg Saint Jacques, 75014 Paris, France, and.
Álvaro Cuesta-Marbánthe Department of Physiology, Université de Lausanne, Rue du Bugnon 7, 1005 Lausanne, Switzerland.
Christian Widmannthe Department of Physiology, Université de Lausanne, Rue du Bugnon 7, 1005 Lausanne, Switzerland.
Edith Browaeys-PolyFrom the Université de Lille 1, Sciences et Technologies, Team Signal Division Regulation, CNRS UMR 8576, SN3, 59655 Villeneuve d'Ascq Cedex, France.
Université de Lille · FRUniversity of Lausanne · CHSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast growth factor receptors (FGFRs) are involved in proliferative and differentiation physiological responses. Deregulation of FGFR-mediated signaling involving the Ras/PI3K/Akt and the Ras/Raf/ERK MAPK pathways is causally involved in the development of several cancers. The caspase-3/p120 RasGAP module is a stress sensor switch. Under mild stress conditions, RasGAP is cleaved by caspase-3 at position 455. The resulting N-terminal fragment, called fragment N, stimulates anti-death signaling. When caspase-3 activity further increases, fragment N is cleaved at position 157. This generates a fragment, called N2, that no longer protects cells. Here, we investigated in Xenopus oocytes the impact of RasGAP and its fragments on FGF1-mediated signaling during G2/M cell cycle transition. RasGAP used its N-terminal Src homology 2 domain to bind FGFR once stimulated by FGF1, and this was necessary for the recruitment of Akt to the FGFR complex. Fragment N, which did not associate with the FGFR complex, favored FGF1-induced ERK stimulation, leading to accelerated G2/M transition. In contrast, fragment N2 bound the FGFR, and this inhibited mTORC2-dependent Akt Ser-473 phosphorylation and ERK2 phosphorylation but not phosphorylation of Akt on Thr-308. This also blocked cell cycle progression. Inhibition of Akt Ser-473 phosphorylation and entry into G2/M was relieved by PHLPP phosphatase inhibition. Hence, full-length RasGAP favors Akt activity by shielding it from deactivating phosphatases. This shielding was abrogated by fragment N2. These results highlight the role played by RasGAP in FGFR signaling and how graded stress intensities, by generating different RasGAP fragments, can positively or negatively impact this signaling.

Indexed as

AnimalsCaspase 3Cell Line, TumorEnzyme InhibitorsFemaleFibroblast Growth Factor 1G2 Phase Cell Cycle CheckpointsGene Expression RegulationHumansMechanistic Target of Rapamycin Complex 2MicroinjectionsMitogen-Activated Protein Kinase 1Multiprotein ComplexesNuclear ProteinsOocytesOvaryCaspase 3Enzyme InhibitorsFibroblast Growth Factor 1MAPK1 protein, humanMechanistic Target of Rapamycin Complex 2Mitogen-Activated Protein Kinase 1Multiprotein ComplexesNuclear Proteinsp120 GTPase Activating ProteinPeptide FragmentsPHLPP1 protein, humanPhosphoprotein PhosphatasesProto-Oncogene Proteins c-aktRecombinant Fusion ProteinsTOR Serine-Threonine KinasesAkt PKBcaspasecell signalingfibroblast growth factor receptor (FGFR)GTPase-activating protein (GAP)mitogen-activated protein kinase (MAPK)oocytephosphatasereceptor tyrosine kinaseXenopus

Identifiers

PMID26109071
PMCPMC4528130
OpenAlexW1917148724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.